This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Neoplasm of uncertain or unknown behaviour of endocrine glands내분비선의 행동양식 불명 또는 미상의 신생물

Contents and key points
ItemDetails
A. Classification codesICD-10: D44 (Neoplasm of uncertain or unknown behavior of endocrine glands) | Special Copayment Reduction: V193 (Special Copayment Reduction for cancer: copayment 5% for 5 years from the registration date)
B. SynonymsThyroid neoplasm of uncertain behavior (D44.0), adrenal tumor of uncertain behavior (D44.1, including pheochromocytoma), parathyroid of uncertain behavior (D44.2), pituitary of uncertain behavior (D44.3), craniopharyngioma (D44.4), pineal of uncertain behavior (D44.5), MEN syndrome-associated tumors
C. Adult onsetAdrenal incidentalomas and pituitary incidentalomas are commonly found on imaging in adults and are mostly nonfunctioning. Pheochromocytoma can occur at any age but is most common in the 30s~50s.
1. HistoryThe history of endocrine oncology began with the recognition of endocrine organs in the late 19th century and was modernized through the characterization of MEN syndromes and the discovery of the VHL gene.
2. CausesMEN1/MEN2 syndromes, VHL disease, SDH mutations, radiation exposure, and exogenous hormones are the main risk factors, though sporadic cases are more common.
3. GeneticsMEN1 (11q13), RET (10q11), VHL (3p25), SDH (A/B/C/D), CDKN1B, and MAX gene mutations are the key genes of hereditary endocrine tumors.
4. General epidemiologyAdrenal incidentalomas are found in about 3~5% of adults undergoing CT; pituitary incidentalomas in about 10~15%. Pheochromocytoma occurs in about 2~8 per 100,000.
5. PathophysiologyAbnormalities of the pseudohypoxia pathway (SDH and VHL mutations → HIF-1α stabilization) and kinase signaling pathway (RET, MEN1 → PI3K/mTOR) are the two main pathogenic axes.
6. SymptomsVarious symptoms due to hormone hypersecretion or compression; typical examples are the triad of headache, hypertension, and sweating in pheochromocytoma, the Cushing syndrome phenotype, and mass-effect symptoms of pituitary tumors.
7. SignsObesity and moon face (Cushing), paroxysmal hypertension and tachycardia (pheochromocytoma), visual field defects and headache (pituitary), signs of hypercalcemia (parathyroid), acral enlargement (acromegaly).
8. ScreeningRegular biochemical testing and imaging follow-up in families with MEN1, MEN2, and VHL syndromes; urine screening tests for pheochromocytoma are recommended in hypertensive patients.
9. DiagnosisEndocrine function tests, CT, MRI, 68Ga-DOTATATE PET-CT (neuroendocrine tumors), MIBG scan, and gene panel testing are the key diagnostic tools.
10. TreatmentSurgical resection is the first-line treatment for most endocrine neoplasms; medical therapy such as dopamine agonists and somatostatin analogues is used for pituitary tumors.
11. PrognosisAdrenal and pituitary incidentalomas mostly have a benign course; pheochromocytoma is malignant in about 10~17%; MEN-associated tumors vary by genotype.
12. PreventionEarly genetic diagnosis of hereditary syndromes, regular biochemical and imaging follow-up, and prophylactic thyroidectomy in RET-mutant MEN2 are the key prevention strategies.
13. ReferencesMultiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis … and 9 other papers

1. History

The history of endocrine gland oncology begins in the late 19th century as the functions of the endocrine organs were successively elucidated. In 1855, Thomas Addison described adrenal insufficiency, and in 1896, George Oliver and Edward Sharpey-Schafer discovered the pressor effect of adrenal extract (adrenaline). In the 1920s, tumors originating in the adrenal gland (pheochromocytoma) began to be recognized clinically, and in 1926 Charles Mayo performed the first successful pheochromocytoma resection.

The history of multiple endocrine neoplasia (MEN) begins with Erdheim's 1903 report of simultaneous hyperplasia of several endocrine glands. In 1954, Paul Werner systematized the co-occurrence of parathyroid, pituitary, and pancreatic islet cell tumors as "MEN type 1 (Werner syndrome)". In 1961, John Sipple described the co-occurrence of medullary thyroid carcinoma, pheochromocytoma, and parathyroid hyperplasia, which was later named "MEN type 2". The MEN1 gene (long arm of chromosome 11) was identified in 1997 and RET (the MEN2-associated proto-oncogene) in 1993.

The classification of pituitary tumors was founded on the work of Harvey Cushing in the early 1900s. Cushing first described Cushing disease (pituitary ACTH-secreting tumor) and classified pituitary adenomas clinically and histologically. The concept of adrenal incidentaloma emerged after the spread of CT in the 1980s, and guidelines for evaluating adrenal incidentalomas were subsequently published by several societies. The 2022 revised WHO classification of endocrine tumors (5th edition) expanded the introduction of molecularly based classification of endocrine neoplasms.


2. Causes

The causes of D44 neoplasms of uncertain behavior of endocrine glands are divided into hereditary and sporadic. MEN1 syndrome is an autosomal dominant disorder caused by germline mutations of the MEN1 gene (11q13), characteristically accompanied by parathyroid hyperplasia/adenoma, pituitary adenoma (mainly prolactinoma or nonfunctioning adenoma), pancreatic and duodenal neuroendocrine tumors, and bronchial carcinoid. Endocrine tumors in MEN1 patients occur at a much younger age (20s~30s) than in the general population. MEN2A/2B is caused by germline mutations of the RET proto-oncogene and is characterized by medullary thyroid carcinoma, pheochromocytoma, and parathyroid hyperplasia (MEN2A).

In VHL (von Hippel-Lindau) syndrome, VHL gene (3p25) mutations cause pheochromocytoma, paraganglioma, clear cell renal carcinoma, retinal hemangioma, and central nervous system hemangioblastoma. SDH (succinate dehydrogenase) gene mutations (SDHA/B/C/D) are an important genetic cause of pheochromocytoma and paraganglioma. MAX gene mutations and TMEM127 mutations are also associated with hereditary pheochromocytoma. Radiation, especially after head and neck radiation therapy, is associated with hypopituitarism and the development of thyroid tumors of uncertain behavior. Exogenous estrogen and progestin administration can promote the growth of pituitary adenomas, especially prolactinomas.


3. Genetics

The genetics of neoplasms of uncertain behavior of endocrine glands differ by site, but several syndromes share overlapping gene pathways. The MEN1 gene encodes the nuclear protein menin, which is involved in regulating histone methylation, and its loss of function results in multiple endocrine gland tumors. Menin binds to the MLL/KMT2A histone methyltransferase complex to regulate transcription of tumor suppressor genes, and its loss of function promotes CDK4/6-dependent cell cycle progression.

In pheochromocytoma, mutations in the SDH complex genes play a central role. Loss of SDH function causes accumulation of succinate, which inhibits 2-oxoglutarate (2-OG)-dependent dioxygenases (TET2, EGLN, etc.), thereby stabilizing HIF-1α. As a result, angiogenic factors (VEGF) are overexpressed and a pseudohypoxic state is induced, promoting tumor growth. In pituitary adenomas, CDKN1B (p27Kip1) mutations cause a MEN1 syndrome-like phenotype (MEN4), and AIP gene mutations are important in familial isolated pituitary adenoma (FIPA). CDC73 (HRPT2) gene mutations, PRKAR1A mutations (associated with Carney complex), and MEN1 mutations are found in parathyroid carcinoma.


4. General epidemiology

The epidemiology of neoplasms of uncertain behavior of endocrine glands differs greatly by type. Adrenal incidentaloma is a very common incidental lesion found in about 3~5% of adults undergoing abdominal CT. It increases with age and is observed in about 10% of people in their 70s or older. About 70~80% of adrenal incidentalomas are nonfunctioning adrenal adenomas, about 5% are pheochromocytomas, about 1~2% are adrenocortical carcinomas, and about 2% are metastatic lesions. Therefore, assessment of function and malignancy is essential for a newly found adrenal incidentaloma.

Pituitary incidentalomas are found in about 10~15% of adults undergoing MRI, and most (about 90%) are microadenomas less than 10mm in diameter. Pituitary macroadenomas (>10mm) are rare, found in about 0.2%. The incidence of pheochromocytoma is about 2~8 per 100,000 per year, and it is found in about 0.2~0.4% of all hypertensive patients. About 30~40% of pheochromocytomas are hereditary (SDH, VHL, RET, NF1, etc.), and the rest are sporadic. The prevalence of MEN1 syndrome is about 1~3 per 100,000 population, and prevalence data from Asia, including Korea, are limited.


5. Pathophysiology

The pathogenesis of neoplasms of uncertain behavior of endocrine glands is broadly divided into two main molecular pathways. The pseudohypoxic pathway is triggered by SDH, VHL, FH, and MDH2 gene mutations. With loss of SDH or VHL function, HIF-1α is stabilized even in the presence of oxygen, and hypoxia-response genes such as VEGF (vascular endothelial growth factor), EPO (erythropoietin), and GLUT1 are overexpressed. This promotes strong angiogenesis and a shift in glucose metabolism, creating a microenvironment that supports rapid tumor growth.

Abnormalities of kinase signaling pathways are triggered by RET (MEN2), NF1, and MAX mutations. Activating RET mutations simultaneously activate the PI3K/AKT/mTOR and RAS/MAPK pathways, causing unregulated proliferation of endocrine cells (thyroid medullary C cells, adrenal medullary chromaffin cells). Loss of MEN1/menin function reduces histone H3K4 methylation, decreasing expression of CDK inhibitors such as CDKN1B and CDKN2C and promoting cell cycle progression from G1 → S phase. In the development of adrenocortical tumors, the WNT/β-catenin pathway (CTNNB1 mutations), PRKAR1A mutations (cAMP-PKA pathway), and IGF-2 overexpression play important roles.


6. Symptoms

The symptoms of D44 neoplasms of uncertain behavior of endocrine glands vary greatly with hormone secretion and tumor location and size. In functioning tumors, syndromes appear according to the characteristics of the hormone secreted in excess. The classic triad of pheochromocytoma is headache, sweating, and palpitations; when all three are present, pheochromocytoma is likely. Blood pressure presents as sustained hypertension (50%) or paroxysmal hypertension (50%), and during a hypertensive crisis headache, profuse sweating, pounding heart, and anxiety accompany it. In Cushing syndrome (adrenal ACTH-independent cortisol excess), weight gain (central obesity), skin striae, elevated blood glucose, muscle weakness, and mood changes appear.

In pituitary adenomas, various symptoms of hormone hypersecretion appear depending on the tumor type. Prolactinomas cause amenorrhea and galactorrhea in women, and sexual dysfunction and gynecomastia in men. Growth hormone-secreting adenomas cause acromegaly (enlargement of bone, soft tissue, tongue, nose, hands and feet, change in facial appearance). Adrenocorticotropic hormone (ACTH)-secreting tumors cause Cushing syndrome. When the tumor is large, compression of surrounding structures causes visual field defects (bitemporal hemianopia due to optic chiasm compression), headache, and ophthalmoplegia (cavernous sinus invasion). Nonfunctioning tumors present mainly with compressive symptoms from increasing size and hypopituitarism (hypothyroidism, adrenal insufficiency, hypogonadism).


7. Signs

On physical examination in pheochromocytoma, hypertension (systolic > 200mmHg possible), profuse sweating during attacks, pallor followed by flushing, and orthostatic hypotension are found. On palpation of the thyroid region, a neck mass may be found, and in medullary thyroid carcinoma a firm nodule with irregular margins is palpable. In hyperparathyroidism (hypercalcemia), muscle weakness, decreased deep tendon reflexes, Chvostek and Trousseau signs (negative in hypercalcemia, positive in hypocalcemia), and psychiatric symptoms (confusion, lethargy) appear. Typical physical signs of Cushing syndrome include moon face, buffalo hump (fat accumulation in the neck), purple abdominal striae, proximal muscle atrophy, and thinning of the skin.

In patients with acromegaly, enlarged hands and feet, mandibular prognathism, diastema, thickened skin, a deep voice due to enlargement of the subglottic region, and snoring and sleep apnea are observed. In pituitary macroadenoma, bitemporal hemianopia is characteristically found on visual field testing. In patients with hypopituitarism, signs of panhypopituitarism such as pale skin, dry skin, bradycardia, myxedematous face, and reduced pubic and axillary hair are observed.


8. Screening

The key to screening for neoplasms of uncertain behavior of endocrine glands is a targeted approach directed at high-risk groups rather than the general population. In patients with confirmed MEN1 syndrome and their families, for carriers of pathogenic variants, regular biochemical testing (calcium, PTH, prolactin, IGF-1, fasting glucose/insulin, gastrin) and imaging follow-up (annual abdominal CT/MRI, brain MRI every 3 years) of the parathyroid, pituitary, and pancreas are recommended from a young age (around age 10). In MEN2A variant carriers, the timing of prophylactic thyroidectomy is determined by the type of RET mutation, and regular serum calcitonin and catecholamine tests are performed.

In patients newly diagnosed with pheochromocytoma, even if it appears sporadic, identification of a hereditary cause through SDH, VHL, RET, NF1, MAX, and TMEM127 gene testing is recommended (currently about 30~40% are hereditary). Families of confirmed hereditary pheochromocytoma carriers need genetic counseling along with follow-up by regular plasma metanephrine measurement and abdominal MRI. In hypertensive patients whose blood pressure is difficult to control or accompanied by paroxysmal elevations, or who have an adrenal incidentaloma, pheochromocytoma is screened with plasma or 24-hour urine metanephrine testing. For adrenal incidentalomas, function and malignancy are evaluated immediately upon discovery with hormone testing (cortisol suppression test, blood catecholamines/metanephrines, aldosterone/renin ratio) and imaging characteristic analysis (HU value < 10 strongly suggests adenoma).


9. Diagnosis

Diagnosis of D44 endocrine gland neoplasms is achieved through the integration of biochemical functional assessment, imaging, and histopathological examination. Biochemical testing is the key to diagnosing functional tumors. For pheochromocytoma, plasma fractionated metanephrines are the first-line biochemical test with the highest sensitivity (about 97%) and specificity (about 93%), and 24-hour urinary metanephrines and catecholamine measurements are used as complementary tests. For the diagnosis of Cushing syndrome, the 1 mg overnight dexamethasone suppression test, 24-hour urinary free cortisol, and midnight salivary cortisol are used. For pituitary adenomas, IGF-1 (growth hormone excess), prolactin, FSH/LH/TSH/ACTH, baseline cortisol, and dynamic testing are used.

In imaging, CT and MRI are used for localization and assessment of size and morphology. In adrenal tumors, an HU (Hounsfield unit) < 10 on unenhanced CT is highly specific for an adenoma. For pituitary adenomas, dynamic contrast-enhanced MRI is the standard, and microadenomas enhance later than the pituitary gland. As functional imaging, 123I-MIBG (metaiodobenzylguanidine) scintigraphy and 68Ga-DOTATATE PET-CT are used for staging and evaluation of metastasis in pheochromocytoma and paraganglioma. 68Ga-DOTATATE PET-CT has higher sensitivity than MIBG and is useful for detecting metastatic or multiple lesions. In histopathology, it is often difficult to determine malignancy in endocrine tumors, and in pheochromocytoma only distant metastasis is accepted as definitive evidence of malignancy.


10. Treatment

Treatment of D44 endocrine gland neoplasms of uncertain behavior is individualized according to tumor origin, hormonal activity, size, and location. Surgery is the first-line treatment for most endocrine neoplasms. For pheochromocytoma, alpha-blocker (phenoxybenzamine, doxazosin) pretreatment for 10 to 14 days before surgery is mandatory, followed by laparoscopic or open adrenalectomy. Adequate alpha blockade is essential to prevent intraoperative hypertensive surges and arrhythmias. For pituitary adenomas, transsphenoidal endoscopic surgery is the standard first-line treatment in most cases except prolactinoma. In prolactinoma, dopamine agonists (cabergoline, bromocriptine) are the first-line drug treatment, achieving prolactin normalization and tumor size reduction in most patients.

In growth hormone excess (acromegaly) not cured by surgery, somatostatin analogs (octreotide, lanreotide) and a growth hormone receptor antagonist (pegvisomant) are used. In adrenocortical hyperfunction (Cushing disease) with incomplete remission after surgery, steroidogenesis inhibitors (metyrapone, ketoconazole, osilodrostat) and pasireotide (a somatostatin analog) are used. In MEN1, multidisciplinary sequential treatment of pituitary, pancreatic, and parathyroid tumors and the use of everolimus (an mTOR inhibitor) are considered. In metastatic pheochromocytoma, 131I-MIBG radiotherapy, sunitinib, and cabozantinib are being used or studied in clinical trials.


11. Prognosis

The prognosis of D44 endocrine gland neoplasms of uncertain behavior varies greatly depending on whether the tumor is functional, whether a hereditary syndrome is present, and whether malignant transformation has occurred. About 98% of nonfunctioning adrenal incidentalomas do not grow for years, and malignant transformation is rare. Surgery is considered if the size increases on follow-up (> 4cm or growth of 1cm or more within 1 year) or if imaging characteristics change. Metastatic (malignant) lesions develop in about 10 to 17% of pheochromocytomas, and the malignant transformation rate is particularly high, about 30 to 40%, in SDHB-mutated pheochromocytoma. The 5-year survival rate of metastatic pheochromocytoma is about 40 to 60%.

The prognosis of pituitary adenoma depends on whether complete resection is achieved and on recurrence. The complete remission rate after surgery for microadenomas is 80 to 90%, with a low recurrence rate. Macroadenomas are difficult to resect completely and have a high recurrence rate, and radiotherapy (stereotactic radiosurgery or fractionated radiotherapy) is used as an adjunct. In MEN1 patients, multiple endocrine tumors occur simultaneously, requiring lifelong multidisciplinary follow-up, and the overall prognosis depends largely on the aggressiveness of the pancreatic neuroendocrine tumor. In MEN2A patients, the prognosis of medullary thyroid carcinoma varies with the type of RET codon variant, and most cases can be cured by early prophylactic thyroidectomy.


12. Prevention

Prevention of endocrine gland neoplasms of uncertain behavior centers on early diagnosis of hereditary syndromes and preventive treatment. In carriers of pathogenic RET variants associated with MEN2A or MEN2B, prophylactic thyroidectomy is the most effective preventive measure, achieving a cure before the development of medullary thyroid carcinoma (MTC). The timing of surgery is determined according to the ATA (American Thyroid Association) risk classification, and resection within 6 months of birth is recommended for carriers of highest-risk variants (C634F/Y/S/R/W/G, M918T, etc.). In MEN1 syndrome, early testing of families with an identified MEN1 variant and regular follow-up detect multiple tumors at an early stage and prevent complications.

In carriers of hereditary pheochromocytoma syndromes (SDH, VHL), regular biochemical testing and MRI follow-up allow detection at the small-tumor stage, making laparoscopic partial adrenalectomy (preserving adrenal function) possible. Through regular follow-up of adrenal incidentalomas, functional activation and size increase are detected early, allowing therapeutic intervention before malignant transformation. In patients with pituitary incidentalomas, regular MRI (for the first 12 months, then every 2 to 3 years) and hormonal evaluation detect size changes and functional abnormalities early. In patients with a history of radiation exposure, regular endocrine function evaluation detects hypopituitarism and the development of secondary tumors early.


13. References

  1. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990-3011. DOI: 10.1210/jc.2012-1230. PMID: 22723327.

  2. Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567-610. DOI: 10.1089/thy.2014.0335. PMID: 25810047.

  3. Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-1942. DOI: 10.1210/jc.2014-1498. PMID: 24893135.

  4. Broder MS, Cai B, Chang E, et al. Epidemiology of acromegaly in the United States: an analysis of administrative databases. Endocr Pract. 2016;22(11):1302-1310. DOI: 10.4158/EP161746.OR. PMID: 27537540.

  5. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93(5):1526-1540. DOI: 10.1210/jc.2008-0125. PMID: 18334580.

  6. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94(5):1509-1517. DOI: 10.1210/jc.2008-2455. PMID: 19208732.

  7. Castinetti F, Moley J, Mulligan L, Waguespack SG. A comprehensive review of MEN2B. Endocr Relat Cancer. 2018;25(2):T29-T39. DOI: 10.1530/ERC-17-0400. PMID: 29046363.

  8. Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline. Eur J Endocrinol. 2016;175(2):G1-G34. DOI: 10.1530/EJE-16-0467. PMID: 27390021.

  9. Ghigo E, Masel B, Aimaretti G, et al. Consensus guidelines on screening for hypopituitarism following traumatic brain injury. Brain Inj. 2005;19(9):711-724. DOI: 10.1080/02699050400023317. PMID: 16175833.

  10. Brierley JD, Gospodarowicz MK, Wittekind C (eds). TNM Classification of Malignant Tumours (8th ed). John Wiley & Sons. 2017. ISBN: 978-1-119-26357-9.